Outcomes of Strabismus Surgery Following Teprotumumab Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : New York, NY : Elsevier Science
      Original Publication: [Chicago, etc., Ophthalmic Pub. Co., etc.]
    • Subject Terms:
      Oculomotor Muscles*/surgery ; Oculomotor Muscles*/physiopathology ; Graves Ophthalmopathy*/surgery ; Graves Ophthalmopathy*/drug therapy ; Diplopia*/physiopathology ; Strabismus*/surgery ; Strabismus*/physiopathology ; Antibodies, Monoclonal, Humanized*/therapeutic use; Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Adult ; Treatment Outcome ; Ophthalmologic Surgical Procedures ; Decompression, Surgical ; Vision, Binocular/physiology
    • Abstract:
      Purpose: To investigate the results of patients undergoing surgical treatment for strabismic diplopia in thyroid eye disease (TED) following teprotumumab.
      Design: Multicenter, retrospective, case series.
      Methods: We report 28 patients who underwent extraocular muscle surgery for strabismic diplopia after treatment with teprotumumab at 7 different academic centers. Elapsed time from last teprotumumab dose to the date of surgery, previous orbital decompression, primary preoperative horizontal and vertical deviation, surgical procedure, and 2-month postoperative results were collected from the patient records.
      Results: Sixteen (57%) patients were diplopia-free after 1 surgery. Three (11%) chose prism spectacles to correct residual diplopia, 2 (7%) used compensatory head posture to resolve diplopia, and 1 (4%) had intermittent diplopia and was functionally improved (choosing no prisms or further surgery). These were considered treatment successes. Three (11%) patients required reoperation, and all were diplopia-free after their second procedure.
      Conclusions: Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.
      (Copyright © 2024. Published by Elsevier Inc.)
    • Accession Number:
      0 (teprotumumab)
    • Publication Date:
      Date Created: 20240108 Date Completed: 20240516 Latest Revision: 20240820
    • Publication Date:
      20240821
    • Accession Number:
      10.1016/j.ajo.2024.01.005
    • Accession Number:
      38191066